bioAffinity Technologies (BIAF) Depreciation & Amortization (CF) (2021 - 2026)
bioAffinity Technologies has reported Depreciation & Amortization (CF) over the past 5 years, most recently at $114518.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 25.92% to $114518.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $464766.0 through Mar 2026, down 23.88% year-over-year, with the annual reading at $504836.0 for FY2025, 16.64% down from the prior year.
- Depreciation & Amortization (CF) was $114518.0 for Q1 2026 at bioAffinity Technologies, down from $123659.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $154588.0 in Q1 2025 and troughed at $773.0 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $113360.0 (2025), against an average of $87339.1.
- Year-over-year, Depreciation & Amortization (CF) soared 7347.48% in 2023 and then decreased 25.92% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $7330.0 in 2022, then surged by 1929.84% to $148787.0 in 2023, then increased by 3.26% to $153632.0 in 2024, then dropped by 19.51% to $123659.0 in 2025, then dropped by 7.39% to $114518.0 in 2026.
- Per Business Quant, the three most recent readings for BIAF's Depreciation & Amortization (CF) are $114518.0 (Q1 2026), $123659.0 (Q4 2025), and $113360.0 (Q3 2025).